Nielsen BioSciences announced the final patient has been successfully enrolled in the CFW-3A trial for CANDIN in common warts ...

If approved, PRGN-2012 would be the first treatment allowed by the FDA for the rare and chronic disease caused by HPV 6 and HPV 11.

Gynecologist Dr. Kim Alexander explains the benefits of HPV testing and midlife vaccination against the virus.